Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DIWSF
ADC Name
Cantuzumab mertansine
Synonyms
C-242 DM1; C-242 May; C242 maytansinoid conjugate; Cantuzumab mertansine; Monoclonal antibody C-242 DM1 conjugate; Monoclonal antibody C-242 May conjugate; Monoclonal antibody huC242-May conjugate; SB-408075; huC242 maytansinoid conjugate; huC242-DM1
   Click to Show/Hide
Organization
ImmunoGen, Inc.
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Research Article
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Cantuzumab
  Antibody Info 
Antigen Name
Mucin-1 (MUC1)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
mertansine
Puchem SID
472397977 , 135315063 , 476269507 , 476262822 , 17397513 , 480408953 , 160687954
Drugbank ID
DB17239
TTD ID
D0N3JT
ChEBI ID
CHEMBL1742997
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  Undisclosed
Phase 1
A phase 1 study that patients with advanced solid tumors and documented CanAg expression were treated with escalating doses of cantuzumab mertansine IV administered three-times a week in a 3 out of 4 weeks schedule. Twenty patients (pts) with colon (11/20),rectal carcinomas (2/20),or other malignancies (7/20) were treated with doses ranging from 30 to 60 mg/m2 per day of cantuzumab mertansine IV three-times a week.

   Click to Show/Hide
Undisclosed  Undisclosed
Phase 1
Patients with CanAg-expressing solid malignancies were treated with escalating doses of cantuzumab mertansine administered IV every 3 weeks. Thirty-seven patients received 110 courses of cantuzumab mertansine at doses ranging from 22 to 295 mg/m2.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
0.00%
Patients Enrolled
Histological documentation of advanced or metastatic epithelial solid tumor which were likely to express the CanAg antigen, that were refractory or resistant to standard chemotherapy, or for which no effective standard therapy exists.
Administration Dosage
IV infusion at an initial dose of 30 mg/m2, three times per week for three consecutive weeks for a total of nine doses.
Experiment 2 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Solid malignancies refractory to standard therapy or for whom no standard therapy existed.
Administration Dosage
IV cantuzumab mertansine was administered at a rate of 1 mg/min for 30 minutes and then increased to 3 mg/min if hypersensitivity phenomena were not observed. Treatment courses were repeated every 3 weeks.
References
Ref 1 Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol. 2008 Oct;62(5):911-9.
Ref 2 Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003 Jan 15;21(2):211-22.